Hikma Pharmaceuticals (LON:HIK) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,926.51 ($24.98) and traded as high as GBX 1,942 ($25.18). Hikma Pharmaceuticals shares last traded at GBX 1,920 ($24.90), with a volume of 415,904 shares traded.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Hikma Pharmaceuticals to a “buy” rating and increased their price target for the stock from GBX 2,100 ($27.23) to GBX 2,400 ($31.12) in a research report on Monday, September 2nd.

Hikma Pharmaceuticals Trading Down 2.5 %

The firm has a market capitalization of £4.12 billion, a PE ratio of 2,853.85, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The firm’s 50-day simple moving average is GBX 1,938.84 and its 200-day simple moving average is GBX 1,926.72.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s payout ratio is 9,538.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.